Biohit Oyj

Earnings Release • Jul 29, 2021

Päivi Siltala new CEO of Biohit Oyj

Päivi Siltala new CEO of Biohit Oyj

Biohit Oyj stock exchange release 29[th] of July 2021 at 09.00 am local time
(EET)

Changes in Management

The Board of Directors of Biohit Oyj has appointed MA Päivi Siltala the CEO of
the company starting September 1, 2021. Siltala is joining Biohit from Johnson &
Johnson where she has been Sales Director.

Siltala is an experienced biotechnology professional with a large international
contact network. She also has a solid track record in managing business
development and growth. Siltala has worked in Biohit 2008-2010 and thus knows
the company and the technology, which speeds up operative integration.

“Siltala’s experience in biotechnology and personal qualities and skills makes
her excellent person to lead and develop Biohit business and operations to
materialize company’s commercial potential in the best possible way”, says Eero
Lehti, Chairman of the Board of Directors.

Beside Biohit and Johnson & Johnson, Siltala has worked in leading sales and
business development positions at Pentax Medical and Cook Medical Endoscopy.

Additional information:
Chairman of the Board of Directors Eero Lehti, Biohit Oyj
tel. +358 9 773 861

investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission
is “Innovating for Health” – we produce innovative products and services to
promote research and early diagnosis. Biohit is headquartered in Helsinki,
Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV)
is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
www.biohithealthcare.com (https://www.globenewswire.com/Tracker?data=ciyb_iZ945H2
z3sK3a9i7Zs03Nkj9jr5Brw7kC1tsoUye5PVgko06PC57Z9BVVT2pXUgp6sn
-tswLd2MUgQOQc8UNXD2BkNm3L02XzRJ7XfJCPaPUqGS1mpI0NZinK5T)